X. Duval, F. Delahaye, A. F. Tattevin, P. Obadia, J. et al., Temporal trends in infective endocarditis in the context of prophylaxis guideline modifications: three successive population-based surveys, J Am Coll Cardiol, vol.59, issue.22, pp.1968-76, 2012.
URL : https://hal.archives-ouvertes.fr/hal-00825449

V. G. Fowler, J. M. Miro, B. Hoen, C. H. Cabell, E. Abrutyn et al., Staphylococcus aureus endocarditis: a consequence of medical progress, JAMA, vol.293, issue.24, pp.3012-3033, 2005.

A. Wang, E. Athan, P. A. Pappas, V. G. Fowler, L. Olaison et al., Contemporary clinical profile and outcome of prosthetic valve endocarditis, JAMA, vol.297, issue.12, pp.1354-61, 2007.

C. Chirouze, C. H. Cabell, V. G. Fowler, N. Khayat, L. Olaison et al., Prognostic factors in 61 cases of Staphylococcus aureus prosthetic valve infective endocarditis from the International Collaboration on Endocarditis merged database, Clin Infect Dis, vol.38, issue.9, pp.1323-1330, 2004.

K. Saeed, A. M. Bal, I. M. Gould, M. Z. David, M. Dryden et al., An update on Staphylococcus aureus infective endocarditis from the International Society of Antimicrobial Chemotherapy (ISAC), Int J Antimicrob Agents, vol.53, issue.1, pp.9-15, 2019.

G. Habib, P. Lancellotti, M. J. Antunes, M. G. Bongiorni, J. Casalta et al., ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM), Eur Heart J, vol.36, issue.44, pp.3075-128, 2015.

L. M. Baddour, W. R. Wilson, A. S. Bayer, V. G. Fowler, I. M. Tleyjeh et al., Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association, Circulation, vol.132, issue.15, pp.1435-86, 2015.

M. Niemi, J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivistö, Pharmacokinetic interactions with rifampicin : clinical relevance, Clin Pharmacokinet, vol.42, issue.9, pp.819-50, 2003.

G. E. Thwaites, M. Scarborough, A. Szubert, E. Nsutebu, R. Tilley et al., Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, doubleblind, placebo-controlled trial, Lancet, vol.391, pp.668-78, 2018.

J. S. Li, D. J. Sexton, M. N. Nettles, R. Fowler, V. G. Ryan et al., Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis, Clin Infect Dis, vol.30, issue.4, pp.633-641, 2000.

M. E. Charlson, P. Pompei, K. L. Ales, and C. R. Mackenzie, A new method of classifying prognostic comorbidity in longitudinal studies: development and validation, J Chronic Dis, vol.40, issue.5, pp.373-83, 1987.

A. W. Karchmer, G. L. Archer, and W. E. Dismukes, Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy, Ann Intern Med, vol.98, issue.4, pp.447-55, 1983.

A. W. Karchmer, G. L. Archer, and W. E. Dismukes, Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis, Rev Infect Dis, 1983.

D. Drinkovi?, A. J. Morris, S. Pottumarthy, D. Macculloch, and T. West, Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis, J Antimicrob Chemother, vol.52, issue.5, pp.820-825, 2003.

N. K. Shrestha, S. Y. Shah, H. Wang, S. T. Hussain, G. B. Pettersson et al., Rifampin for Surgically Treated Staphylococcal Infective Endocarditis: A Propensity Score-Adjusted Cohort Study, Ann Thorac Surg, vol.101, issue.6, pp.2243-50, 2016.

D. J. Riedel, E. Weekes, and G. N. Forrest, Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus, Antimicrob Agents Chemother, vol.52, issue.7, pp.2463-2470, 2008.

W. Zimmerli, A. F. Widmer, M. Blatter, R. Frei, and P. E. Ochsner, Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group, JAMA, vol.279, issue.19, pp.1537-1578, 1998.

Z. Zheng and P. S. Stewart, Penetration of rifampin through Staphylococcus epidermidis biofilms, Antimicrob Agents Chemother, 2002.

R. Saginur, M. Stdenis, W. Ferris, S. D. Aaron, F. Chan et al., Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections, Antimicrob Agents Chemother, vol.50, issue.1, pp.55-61, 2006.

M. Revest, J. C. Boudjemaa, R. Caillon, J. , L. Mabecque et al., New in vitro and in vivo models to evaluate antibiotic efficacy in Staphylococcus aureus prosthetic vascular graft infection, J Antimicrob Chemother, vol.71, issue.5, pp.1291-1300, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01274236

S. Rieg, I. Joost, V. Weiß, G. Peyerl-hoffmann, C. Schneider et al., Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management, Clin Microbiol Infect, vol.23, issue.6, pp.41-59, 2017.

L. P. Park, V. H. Chu, G. Peterson, A. Skoutelis, T. Lejko-zupa et al., Validated Risk Score for Predicting 6-Month Mortality in Infective Endocarditis, J Am Heart Assoc, vol.5, issue.4, p.3016, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01305479

L. Fauchier, L. Pericart, T. Bourguignon, T. Genet, A. Bisson et al., Comparison of Outcome of Possible Versus Definite Infective Endocarditis Involving Prosthetic or Bioprosthetic Heart Valves, Am J Cardiol, vol.120, issue.10, pp.1884-90, 2017.